Everything tagged "cash flow" across research, earnings, and macro.
113 articles
Vertex combines a dominant cystic fibrosis franchise with early diversification in rare disease and acute pain. The stock looks like a disciplined Buy, but valuation still depends on execution across ALYFTREK, CASGEVY, JOURNAVX, and the renal pipeline.
AT&T is a Buy for investors seeking a defensive telecom with improving fiber economics, stable wireless growth, and a valuation that still looks discounted. Q1 2026 showed stronger revenue, EBITDA, and EPS, while the company continues to convert network investment into customer gains.
Copart remains a high-quality compounder with elite margins, a fortress balance sheet, and durable international growth levers. Near-term revenue growth has slowed, but the stock still screens as a Buy on valuation and cash generation.
Moderna is a transition story with real mRNA platform strength, but weak earnings and heavy COVID dependence keep it in Hold territory. The stock’s appeal hinges on late-stage pipeline catalysts and a cash runway that supports the pivot.
Apogee is a small-cap building-products name with strong cash generation, a healthy balance sheet, and a mix shift toward higher-margin businesses. Offsetting that are cyclical pressure in Architectural Glass and a still-muted earnings profile.
TD SYNNEX is pairing resilient distribution cash flow with a rapidly scaling Hyve infrastructure business. Strong revenue and EPS growth support a constructive Buy view, though valuation has tightened after a sharp run-up.
Trip.com Group combines fast international travel growth with strong profitability and a net cash balance. The stock looks attractive despite slower near-term guidance and regulatory risk.
Uber has evolved into a profitable scaled marketplace, with 2025 revenue up 18% and free cash flow surging as Uber One and cross-platform usage deepen the moat.
Korn Ferry combines steady fee-revenue growth, strong free cash flow, and a net cash balance sheet with a valuation that still looks reasonable. The report argues the stock remains attractive below fair value despite cyclical labor-market risk.
AbbVie is showing that its post-Humira rebuild is real, with Skyrizi and Rinvoq driving strong growth and full-year guidance moving higher. Heavy debt and a negative equity position remain the main risks, but cash flow and earnings power still look compelling.
Infosys is a cash-rich IT services franchise with strong large-deal momentum, steady margins, and a measured FY27 growth outlook. The stock looks like a disciplined compounder rather than a breakout story.
Talen’s latest deal matters because it adds real generation and cash flow underneath the AI-data-center story. That makes TLN look less like a hype proxy and more like a power company with a stronger earnings base.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator